# A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

> **NCT04772989** · PHASE1 · COMPLETED · sponsor: **Arcus Biosciences, Inc.** · enrollment: 94 (actual)

## Conditions studied

- Advanced Solid Tumor
- Non Small Cell Lung Cancer (NSCLC)
- Melanoma
- Cervical Cancer
- Multiple Myeloma
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma (DLBCL)
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Cancer

## Interventions

- **DRUG:** AB308
- **DRUG:** Zimberelimab

## Key facts

- **NCT ID:** NCT04772989
- **Lead sponsor:** Arcus Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-19
- **Primary completion:** 2025-08-25
- **Final completion:** 2025-08-25
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2025-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04772989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04772989, "A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04772989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*